Barr E S & CO Zentalis Pharmaceuticals, Inc. Transaction History
Barr E S & CO
- $1.61 Billion
- Q1 2025
A detailed history of Barr E S & CO transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Barr E S & CO holds 40,000 shares of ZNTL stock, worth $50,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,000Holding current value
$50,000% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
140Shares Held
59.1MCall Options Held
7.9KPut Options Held
42.5K-
Matrix Capital Management Company, LP Waltham, MA14MShares$17.4 Million6.94% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$4.08 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.07MShares$3.84 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC2.1MShares$2.62 Million23.31% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $71.2M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...